| 32.6357 -2.014 (-5.81%) | 10-24 14:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.88 | 1-year : | 47.74 |
| Resists | First : | 35 | Second : | 40.88 |
| Pivot price | 28.32 |
|||
| Supports | First : | 27.26 | Second : | 22.47 |
| MAs | MA(5) : | 32.65 |
MA(20) : | 28.13 |
| MA(100) : | 22.95 |
MA(250) : | 16.6 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 90.8 |
D(3) : | 92.2 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 54.29 | Low : | 4.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTHS ] has closed below upper band by 17.7%. Bollinger Bands are 60.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 35.04 - 35.17 | 35.17 - 35.28 |
| Low: | 33.26 - 33.43 | 33.43 - 33.56 |
| Close: | 34.4 - 34.66 | 34.66 - 34.86 |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Mon, 08 Sep 2025
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire
Tue, 02 Sep 2025
Oppenheimer initiates Pelthos Therapeutics stock with Outperform rating - Investing.com
Mon, 18 Aug 2025
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update - Sahm
Thu, 10 Jul 2025
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease - Yahoo Finance
Thu, 03 Jul 2025
Rare in 2025: Triangle gains public company - The Business Journals
Wed, 02 Jul 2025
PTHS Stock Price and Chart — AMEX:PTHS - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|